Acceptability of Vaccination against HIV : A Mapping of Togolese People’s Positions by Kpanake, Lonzozou et al.
1 
 
Acceptability of Vaccination against HIV: A Mapping of Togolese People’s Positions 
 
 
 
 
To cite this article: 
Kpanake, L., Gbandey, S., Sorum, P. C., & Mullet, E. (2016). Acceptability of 
vaccination against HIV: a mapping of Togolese people’s positions. Journal of 
Health Psychology. doi: 10.1177/1359105316639440. Epub: 31 March 2016. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Abstract 
Progress is being made in the development of an effective HIV vaccine. Once the vaccine 
is available, an important public health goal will be its widespread uptake in sub-Saharan 
Africa, home to 70% of new HIV infections worldwide. It is important, therefore, to 
begin planning how to promote its widespread uptake there. The aim of this study was to 
map the different personal positions regarding HIV vaccination of people living in Togo, 
West Africa. From January to April 2014, we recruited 363 adult participants who were 
asked to indicate their level of willingness to receive a future HIV vaccine under different 
conditions varying as a function of five factors: perceived susceptibility to HIV infection; 
effectiveness of the vaccine; perceived severity of AIDS; cost of the vaccine; and 
influence of the family. Five qualitatively different positions were found, which were 
labelled Unconditional acceptance (49%), Depends on cost/effectiveness ratio (20%), 
Depends on cost (18%), Total indecision (10%) and Complete reluctance (3%). Members 
of the wealthier segment of society were less often members of the unconditional 
acceptance cluster and more often members of the cost/effectiveness cluster than others. 
The diversity of people’s positions regarding a future HIV vaccine implies that HIV 
vaccination strategies in Togo and other African countries will need to be tailored in 
design and implementation rather than “one size fits all” interventions. 
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Introduction 
The development of a preventive HIV vaccine offers the best long-term hope of 
managing the impact of the AIDS pandemic that is ravaging sub-Saharan Africa 
(International AIDS Vaccine Initiative, 2009), where 70% of the 2.7 million new HIV 
infections worldwide in 2012, and 70% of all AIDS deaths occurred (UNAIDS, 2013). 
Progress is being made in the development of an effective HIV vaccine (Rappuoli and 
Aderem, 2011; Ross et al., 2010); however, findings from studies about the willingness 
of African people to participate in HIV vaccine trials (Jaspan et al. 2006; Smit et al. 
2006) and about the acceptability of a potential HIV vaccine (Bishai, et al. 2004; Sayles, 
et al. 2010) strongly suggest that the advent of a HIV vaccine would not guarantee its 
uptake. It is important, therefore, to begin planning how to promote its widespread 
uptake.  
A recent systematic review suggests that people vary considerably in their level of 
willingness to be vaccinated against HIV, ranging from 37.2 to 94 on a 100-point scale 
(Newman and Logie, 2010). In addition, the review has identified five broad factors 
impacting acceptability of the vaccine, as suggested by health-protective behavior 
theories (Weinstein, 1993): perceived susceptibility to HIV infection; effectiveness of the 
vaccine; perceived severity of AIDS; cost of the vaccine; and perceived social approval 
of vaccination. Nevertheless, very little is known about the relative contributions of these 
factors on African people’s willingness to receive the vaccine and about the possibly 
diverse vaccination positions of these people. Addressing this gap in knowledge is 
important in order to be able to tailor promotion of HIV vaccination to different people’s 
views and needs (Butler, 2015). 
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Methods 
The study was conducted from January to April 2014. Ethics approval for the study was 
obtained from the Institutional Review Board of the University of Québec-Teluq.  
Study setting 
The study was conducted in Togo, a sub-Saharan African country with a population of 7 
million (WHO, 2015) that faces a generalized HIV epidemic (CNLS-IST, 2015). In Togo, 
the HIV prevalence is 2.5%, with an estimated incidence of 6649 in 2011 ;AIDS remains 
the most common cause of death, accounting for 17% of all deaths (CNLS-IST, 2015). 
The study site was Lomé, the capital city, with a population of 1.5 million (United 
Nations, 2015), where the prevalence of HIV is the highest in the country (3.5%) (CNLS-
IST, 2015). In Lomé, HIV is predominantly transmitted through heterosexual contacts; 
women are twice as likely to be infected as men, and sex workers are the most seriously 
affected (UNAIDS, 2009). People aged between 30-39 years face the most severe burden 
of HIV (CNLS-IST, 2015).  
Study design 
The study was designed in accordance with Anderson’s Functional Theory of Cognition 
(Anderson, 2008). The procedure had two phases. In the familiarisation phase, the 
investigator explained to participants what was expected of them, i.e., that for each 
scenario they were to indicate their level of willingness to receive the vaccine. Next, each 
participant was presented with 18 of the 48 scenarios, in random order. The participant 
then provided ratings of willingness to receive the vaccine. After completing the 18 
ratings, the participant was allowed to compare responses and make changes until 
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satisfied with the entire set of ratings. In the experimental phase, the whole set of 48 
scenarios was presented. Each participant provided ratings at his or her own pace, but 
was neither allowed to compare responses nor allowed to go back and make changes. 
Each participant was tested individually. 
Participants 
The participants were unpaid volunteers recruited and tested by five research assistants, 
well-trained in the research technique used. The assistants contacted a total of 500 people 
walking along the streets of Lomé. The diversity of the population of the capital enabled 
the recruitment of participants with various demographic characteristics. The assistants 
explained to them the purpose of the study, sought their participation, and obtained 
informed consent. This recruitment technique was an efficient and inexpensive means of 
revealing the basic trends needed for what was fundamentally an exploratory study.  
Material 
The material consisted of 48 vignettes composed of all combinations of the five main 
constructs of health-protective behavior theories (Weinstein, 1993): Perceived 
susceptibility to infection (1 chance in 10 or in 50); Effectiveness of the vaccine (70% or 
at least 90%); Perceived severity of AIDS (lethal or chronic owing to the availability of 
treatment); Cost of the vaccine (free, $100, or $200), and Influence of the family 
(encourages or does not encourage). The design was, consequently, a five within-subject 
factor design: Susceptibility × Effectiveness × Severity × Cost × Influence of the family, 
2 × 2 × 2 × 3 × 2. Under each story, there was the question “to what extent would you 
take the vaccine in this case?” as well as an 11-point response scale with a left-hand 
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anchor of “certainly not” (0) and a right-hand anchor of “certainly yes” (10). The cards 
were arranged by chance and in a different order for each participant. 
Statistical analysis 
We detected strong individual differences during preliminary analysis. Accordingly, we 
performed cluster analysis (K-means) on the whole set of raw data as recommended by 
Hoffmans and Mullet (2013). We then conducted separate ANOVAs - full factorial with 
all the interactions- on the data of each cluster, using a Susceptibility x Severity x 
Effectiveness x Cost x Influence of the family, 2 x 2 x 2 x 3 x 2 design. Finally we 
performed Chi² test to test the effects of demographic characteristics. Data was analysed 
using STATISTICA 7. 
 
Results 
Participant profile 
Of the 500 people contacted, 363 (205 men and 158 women) agreed to participate. The 
main reasons for refusal to participate were lack of available time and interest. Eighty-
four per cent of participants chose to be tested at their private homes and the others chose 
a vacant classroom at the local university. The participants took 25 to 35 minutes to 
complete the questionnaires. Their ages ranged from 18 to 62 years (M=24.37, SD=4.63). 
More detailed demographic information is shown in Table 1. 
Positions on vaccination  
The cluster analysis gave a five-cluster solution. The main patterns of data that 
correspond to each cluster are shown in Figure 1. The detailed results of the 
corresponding ANOVAs are shown in Table 2.  
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For 178 participants (49%), the ratings were always high (M=9.01). This cluster 
was called Unconditional acceptance. 
For 71 participants (20%), ratings strongly varied as a function of cost and 
effectiveness; this cluster was called Depends on the cost/effectiveness ratio. The Cost x 
Effectiveness interaction was significant. When the vaccine was fully effective, 
vaccination intention was always high (mean values ranging from 8.00 to 9.54). When it 
was not completely effective, intention depended strongly on cost (mean values ranging 
from 3.14 to 8.07). Also, when AIDS was perceived as not lethal (because of access to 
treatment), intention was lower (M=6.51) than when AIDS was perceived as lethal 
(M=7.53).  
For 65 participants (18%), the ratings considerably varied as a function of the cost 
of the vaccine, and this cluster was called Depends on cost. When the vaccine was free, 
intention was higher (M=9.03) than when it was very costly (M=2.36) or moderately 
costly (M=4.24). Effectiveness had a weak effect. 
For 39 participants (11%), the ratings were concentrated in the middle of the 
willingness scale (M=5.26). When family members encouraged vaccination, intention 
was slightly higher (M=6.37) than when they did not (M=4.16). This cluster was called 
Total hesitation. 
 Finally, for 10 participants (3%), the ratings were always low (M=2.88). None of 
the factors considered in this study had a significant effect. This cluster was called 
Complete reluctance. 
The clusters differed significantly regarding educational level, Chi²(4) = 11.66, p< 
.05, and income, Chi²(4) = 35.53, p < .001. As shown in Table 1, all except one of the 
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members of the Completely reluctant cluster had not had access to post-secondary 
education. Also, wealthier participants ( those earning more than $100 per month, the 
median income in Togo), were less often members of the Unconditional acceptance 
cluster and more often members of the Depends on the cost/effectiveness ratio cluster 
compared to poorer ones (those earning less than $100 per month) (World Bank, 2015). 
 
Discussion  
As expected, several qualitatively different positions were found. This finding is 
consistent with previous studies that show that people’s views regarding vaccination can 
considerably differ and reflect clearly structured personal positions that are partly 
associated with sociodemographic characteristics (Bynum et al., 2012; Ziemer and 
Hoffman, 2013). 
First, vaccination acceptance is already achieved for half of the residents of Lomé. 
People in this group seem to be willing to get the vaccine, irrespective of its level of 
effectiveness, cost, or family attitudes. This result is consistent with the findings of Bishai 
et al. (2004) that a majority of adults in Uganda would be willing to be vaccinated against 
HIV even if the vaccine was not very effective.  Second, for about one person in five, 
acceptability is determined by cost of the vaccine. This result is consistent with previous 
findings in South Africa (Sayles, et al. 2010) and Uganda (Bishai et al., 2004) showing 
that cost might be a barrier to uptake of the vaccine. This suggests that the main emphasis 
of vaccination promotion efforts among people in this group should be on the reduction 
of financial hurdles. Third, for one person in ten, acceptability is determined by influence 
of the family. This suggests that community-based interventions that are engaging and 
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persuasive to people would be necessary for people in this group. These interventions 
should involve community influential leaders (e.g. traditions and religious leaders) and 
local media. Finally, few people (3%) would be unwilling to take the vaccine, whatever 
its characteristics: strong resistance to its use is not expected. 
Limitations of this study include the use of a convenience sample and its 
restriction to people living in one area. As a consequence, generalization of the results to 
people in Togo as a whole must be done with care. In addition, it is difficult to know how 
the views and demographic information of participants differed from those of the people 
who declined to participate. Future studies of the reproducibility of these findings in other 
African countries and among specific HIV-vulnerable populations are needed.  
Despite its limitations, this study is the first to map the acceptability of HIV 
vaccine among people in Africa. It provides insights for the design and implementation of 
tailored HIV vaccination campaigns in Togo and probably in other sub-Saharan African 
countries.  
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Table 1. Demographic Characteristics of the Sample and Clusters. 
       
 
Cluster 
 Characteristic Complete 
Reluctance 
Total 
Hesitat. 
Depends 
on Cost 
Cost/ 
Effectiveness 
Uncondit. 
Acceptance 
Total 
Age 26.20 25.00 25.31 24.75 23.68 24.37 
Gender 
      Males 4 (3) 14 (9) 27 (17) 33 (21) 80 (50) 158 (100) 
Females 6 (3) 25 (12) 38 (19) 38 (19) 98 (47) 205 (100) 
Religion 
      Christian 10 (4) 28 (10) 46 (16) 49 (17) 150 (53) 283 (100) 
Muslim 0 (0) 6 (12) 8 (16) 16 (33) 19 (39) 49 (100) 
Animist 0 (0) 1 (10) 4 (37) 3 (27) 3 (27) 11 (100) 
Atheist 0 (0) 1 (17) 2 (33) 2 (33) 1 (17) 6 (100) 
Education* 
      Primary or Secondary 9 (5) 22 (11) 31 (16) 45 (23) 87 (45) 194 (100) 
Post-secondary or 
Tertiary 1 (1) 17 (10) 34 (20) 26 (15) 91 (54) 169 (100) 
Income* 
      Less than $100 9 (3) 32 (10) 59 (19) 45 (15) 164 (53) 309 (100) 
More than $100 1 (2) 7 (13) 6 (11) 26 (48) 14 (26) 54 (100) 
Total 10 (3) 39 (11) 65 (18) 71 (20) 178 (49) 363 (100) 
Note: * = p<.05 
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Table 2. Results of the ANOVAs for each cluster 
 Effect Error 
  
 
Factor df MS Df MS F p Eta²p 
Cluster : Complete reluctance 
Probability (P) 1 1.12 8 3.90 0.29 .ns .00 
Severity (S) 1 0.75 8 14.19 0.05 .ns .00 
Effectiveness (E) 1 21.33 8 4.69 4.55 .ns .05 
Cost (C) 2 116.97 16 35.77 3.27 .ns .03 
Influence of the 
Family (F) 1 19.59 8 1.18 16.59 .ns 
 
.21 
Cluster: Total hesitation 
Probability (P) 1 38.08 38 9.24 4.12 .ns .10 
Severity (S) 1 439.45 38 92.86 4.73 .ns .11 
Effectiveness (E) 1 7.06 38 12.99 0.54 .ns .01 
Cost (C) 2 20.32 76 20.94 0.97 .ns .02 
Influence of the 
Family (F) 1 2 273.49 38 91.45 24.86 .001 
 
.40 
Cluster: Depends on cost 
Probability (P) 1 58.99 64 9.97 5.91 .ns .08 
Severity (S) 1 10.50 64 16.84 0.62 .ns .01 
Effectiveness (E) 1 191.52 64 12.15 15.76 .001 .20 
Cost (C) 2 12 283.99 128 52.55 233.74 .001 .79 
Influence of the 1 0.00 64 10.77 0.00 .ns  
15 
 
Family (F) .00 
Cluster : Depends on the cost/effectiveness ratio 
Probability (P) 1 329.69 70 12.68 26.00 .001 .27 
Severity (S) 1 824.23 70 32.22 25.58 .001 .27 
Effectiveness (E) 1 10 997.33 70 33.32 330.07 .001 .83 
Cost (C) 2 3 059.89 140 20.69 147.88 .001 .68 
Influence of the 
Family (F) 1 45.09 70 12.63 3.57 .ns 
 
.05 
S x E 1 133.30 70 14.97 8.91 .001 .11 
S x C 2 47.66 140 7.32 6.51 .001 .09 
E x C 2 972.07 140 12.94 75.10 .001 .52 
Cluster : Unconditional acceptance 
Probability (P) 1 4.40 177 2.91 1.51 .ns .01 
Severity (S) 1 2.49 177 8.00 0.31 .ns .00 
Effectiveness (E) 1 180.54 177 5.72 31.57 .001 .14 
Cost (C) 2 49.18 354 6.61 7.44 .001 .04 
Influence of the 
Family (F) 1 80.63 177 6.36 12.69 .001 
 
.06 
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Figure captions 
Figure 1: Mean levels of willingness to receive the vaccine as a function of cost of the 
vaccine and effectiveness of the vaccine. In each panel, willingness to receive the vaccine 
is on the y-axis, the three levels of cost are on the x-axis, and each curve corresponds to 
one level of vaccine effectiveness. Each panel corresponds to one cluster: Complete 
reluctance (Reluctant), Total hesitation (Hesitant), Depends on cost (Cost), Depends on 
the cost/effectiveness ratio (Cost/Effectiveness), and Unconditional acceptance 
(Unconditional).   
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